Alluvium Raised Its McKesson (MCK) Stake as Long-Term Growth Expectations Remain Strong

Alluvium Raised Its McKesson (MCK) Stake as Long-Term Growth Expectations Remain Strong Soumya Eswaran Wed, September 16, 2026 at 5:04 PM GMT+2 3 min read MCK Alluvium Asset Management, an asset management company, released its "Conventum – Alluvium Global Fund" second-quarter 2026 investor letter. The letter can be downloaded here . The second quarter reflected a sharp shift from geopolitical uncertainty and oil market volatility to a powerful equity rally led by semiconductor companies.

Despite the broader market strength, the Fund declined 1. 4% in EUR terms, 2. 2% in USD terms, and 3.

9% in AUD terms. Portfolio results were mixed, with Alphabet benefiting from strong Cloud growth, while Robert Half, H&R Block, and other holdings posted solid gains. However, cable businesses and several healthcare and consumer holdings weighed on performance.

Also, check the fund's top five holdings to see its best picks in 2026. In its second-quarter 2026 investor letter, Conventum – Alluvium Global Fund highlighted McKesson Corporation (NYSE: MCK ). McKesson Corporation (NYSE:MCK) is a leading healthcare services company headquartered in Irving, Texas.

On September 15, 2026, McKesson Corporation (NYSE:MCK) closed at $899. 56 per share. Over the past month.

McKesson Corporation (NYSE:MCK) returned 5. 37% and its shares gained 29. 95% over the past 52 weeks.

McKesson Corporation (NYSE:MCK) has a market capitalization of $106. 21 billion, and its stock has traded with a range of $687. 68 and $999.

00. Conventum – Alluvium Global Fund stated the following regarding McKesson Corporation (NYSE:MCK) in its Q2 2026 investor letter: "Our two healthcare companies had a poor quarter (in terms of share price performance, not business fundamentals). McKesson Corporation (NYSE:MCK), the drug distributor (down 12.

6%), reported its full year results which were perfectly in-line with our expectations. Management provided strong guidance for its next year's earnings, and reiterated its 13%-16% long term growth expectations. After feeding the numbers through our model, our valuation increased by 18%, and with the share price trading below it, we bought a little more such that it accounts for 6.

8% of the Fund. " UBS Says McKesson’s (MCK) FY27 Outlook Looks “Good Enough” After Q4 McKesson Corporation (NYSE:MCK) is not on our list of the 40 Most Popular Stocks Among Hedge Funds . As per our database, 77 hedge fund portfolios held McKesson Corporation (NYSE:MCK) at the end of the second quarter which was 73 in the previous quarter.

While we acknowledge the potential of McKesson Corporation (NYSE:MCK) as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you're looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock . Story Continues In another article , we covered McKesson Corporation (NYSE:MCK) and noted its $2.

25 billion precision medicine acquisition to strengthen its oncology business. In addition, please check out our hedge fund investor letters Q2 2026 page for more investor letters from hedge funds and other leading investors. READ NEXT: 33 Stocks That Should Double in 3 Years and 15 Stocks That Will Make You Rich in 10 Years .

This article is originally published at Insider Monkey .